World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
83
Citations
27565
World Ranking
15527
National Ranking
7828

Youn H. Kim publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Youn H. Kim sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 377 publications — 33rd percentile

33% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Youn H. Kim D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Youn H. Kim sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 83 D-Index — 24th percentile

24% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Youn H. Kim is affiliated with Stanford University in the United States and has a significant publication record in the field of medicine, particularly focusing on dermatology, pathology and forensic medicine, immunology, oncology, and epidemiology.

Their research emphasizes cutaneous lymphoproliferative disorders, lymphoma diagnosis and treatment, CAR-T cell therapy, T-cell and retrovirus studies, fungal infections, nail diseases, and chronic lymphocytic leukemia.

Recent papers authored or co-authored by Youn H. Kim include:

  • Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma, 2021, Nature Communications
  • T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology, 2022, Journal of the National Comprehensive Cancer Network
  • Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC, 2021, Blood
  • NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020, 2020, Journal of the National Comprehensive Cancer Network
  • Highly Multiplexed Phenotyping of Immunoregulatory Proteins in the Tumor Microenvironment by CODEX Tissue Imaging, 2021, Frontiers in Immunology

Frequent co-authors of Youn H. Kim include:

  • Michael S. Khodadoust
  • Julia Scarisbrick
  • Pablo L. Ortiz-Romero
  • Pietro Quaglino
  • Joan Guitart

The scientist publishes regularly in several venues, with a focus on:

  • Blood
  • European Journal of Cancer
  • Journal of Clinical Oncology
  • Journal of the National Comprehensive Cancer Network
  • Blood Advances

The primary research topics explored include:

  • Cutaneous lymphoproliferative disorders research
  • Lymphoma Diagnosis and Treatment
  • CAR-T cell therapy research
  • T-cell and Retrovirus Studies
  • Fungal Infections and Studies
  • Nail Diseases and Treatments
  • Chronic Lymphocytic Leukemia Research

Best Publications

  • Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC).

    Elise Olsen;Eric Vonderheid;Nicola Pimpinelli;Rein Willemze

  • Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma

    Elise A. Olsen;Youn H. Kim;Timothy M. Kuzel;Theresa R. Pacheco

  • Long-term Outcome of 525 Patients With Mycosis Fungoides and Sézary Syndrome: Clinical Prognostic Factors and Risk for Disease Progression

    Youn H. Kim;Howard L. Liu;Serena Mraz-Gernhard;Anna Varghese

  • Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.

    Elise A. Olsen;Sean Whittaker;Youn H. Kim;Madeleine Duvic

  • Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma

    Sean J. Whittaker;Marie-France Demierre;Ellen J. Kim;Alain H. Rook

  • Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell Lymphoma

    Elise Olsen;Madeleine Duvic;Arthur Frankel;Youn Kim

  • TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC)

    Youn H. Kim;Rein Willemze;Nicola Pimpinelli;Sean Whittaker

  • Phase 2 and 3 Clinical Trial of Oral Bexarotene (Targretin Capsules) for the Treatment of Refractory or Persistent Early-Stage Cutaneous T-Cell Lymphoma

    Madeleine Duvic;Ann G. Martin;Youn Kim;Elise Olsen

  • Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

    H Miles Prince;H Miles Prince;Youn H Kim;Steven M Horwitz;Reinhard Dummer

  • European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas.

    Nancy J. Senff;Evert M. Noordijk;Youn H. Kim;Martine Bagot

  • In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study

    Joshua D. Brody;Weiyun Z. Ai;Debra K. Czerwinski;James A. Torchia

  • EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma

    Werner Kempf;Katrin Pfaltz;Maarten H. Vermeer;Antonio Cozzio

  • Non-Hodgkin's Lymphomas

    Andrew D. Zelenetz;Ranjana H. Advani;John C. Byrd;Myron S. Czuczman

  • Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model

    Julia J. Scarisbrick;H. Miles Prince;Maarten H. Vermeer;Pietro Quaglino

  • NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.

    Zelenetz Ad;Abramson Js;Advani Rh;Andreadis Cb

  • Cd30+ cutaneous lymphoproliferative disorders: The stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma ☆

    Howard L. Liu;Richard T. Hoppe;Sabine Kohler;Jeff D. Harvell

  • Clinical Stage IA (Limited Patch and Plaque) Mycosis Fungoides: A Long-term Outcome Analysis

    Youn H. Kim;Reini A. Jensen;Garrett L. Watanabe;Anna Varghese

  • Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project

    Youn H. Kim;Mahkam Tavallaee;Uma Sundram;Katrin A. Salva

  • Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2

    Alexander Ungewickell;Aparna Bhaduri;Eon Rios;Jason Reuter

  • Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.

    Madeleine Duvic;Lauren C. Pinter-Brown;Francine M. Foss;Lubomir Sokol

Frequent Co-Authors

Richard T. Hoppe
Richard T. Hoppe Stanford University
Madeleine Duvic
Madeleine Duvic The University of Texas MD Anderson Cancer Center
Sean Whittaker
Sean Whittaker King's College London
Martine Bagot
Martine Bagot Université Paris Cité
Ranjana H. Advani
Ranjana H. Advani Stanford University
Reinhard Dummer
Reinhard Dummer University of Zurich
Gary S. Wood
Gary S. Wood University of Wisconsin–Madison
Rein Willemze
Rein Willemze Leiden University Medical Center
Pier Luigi Zinzani
Pier Luigi Zinzani University of Bologna
Timothy M. Kuzel
Timothy M. Kuzel Rush University Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a medical education opens doors to a range of online degrees and evolving career paths in healthcare. For those interested in healthcare leadership or administration, check out the top cahme-accredited mha programs. These programs are designed for students aspiring to management roles in hospitals or healthcare organizations and often offer flexible study options.

Nursing professionals looking to elevate their credentials without extensive clinical requirements can explore online rn-bsn programs without clinicals. These programs are tailored for registered nurses seeking to earn their BSN in a convenient online format.

For advanced practice nurses, quick advancement is possible through the shortest msn to dnp program options. These programs help you reach the highest level of clinical nursing expertise in less time.

Alternatively, if you're concerned about hands-on requirements, a dnp program without clinical hours could be a practical solution. These programs can help working professionals advance their doctoral training without additional clinical placements.

Best Scientists Citing Youn H. Kim

Trending Scientists

Recently Published Articles